The Triple Digit IPO: What It Says About Biotech and Wall Street's Appetite for Risk The biotech sector has long been a playground for investors willing to take on extraordinary risk in pursuit of extraordinary rewards.
LB Pharmaceuticals' stock has more than tripled in under a year, sending shockwaves through the financial community. Many are asking whether LB Pharma is ripe for takeover.
LB's success can be attributed to its lead drug candidate, LB 102 – an oral formulation of benzamide, an antipsychotic medication already on the market.